Last updated on April 2018

Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis


Brief description of study

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.

Detailed Study Description

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.

The study is divided into two phases: the screening phase and the evaluation phase. The screening phase includes a screening visit to evaluate subjects' preliminary eligibility for the study. During the screening phase, subjects will collect diary data for at least 4 weeks. The evaluation phase includes 4 weeks of randomized double-blind treatment.

Clinical Study Identifier: NCT02970968

Contact Investigators or Research Sites near you

Start Over

Vanda Pharmaceuticals

Vanda Investigational Site
Miami, FL United States
9.37miles
  Connect »